Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Times Interest Earned (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Times Interest Earned for 7 consecutive years, with -$467.31 as the latest value for Q1 2026.

  • For Q1 2026, Times Interest Earned rose 70.51% year-over-year to -$467.31; the TTM value through Mar 2026 reached -$1098.6, up 17.21%, while the annual FY2025 figure was -$1383.4, 7.87% down from the prior year.
  • Times Interest Earned hit -$467.31 in Q1 2026 for Barinthus Biotherapeutics, up from -$889.62 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $8.84 in Q1 2022 and bottomed at -$2855.4 in Q4 2023.
  • Average Times Interest Earned over 5 years is -$1423.6, with a median of -$1523.8 recorded in 2024.
  • Year-over-year, Times Interest Earned surged 479.46% in 2022 and then crashed 110.04% in 2025.
  • Barinthus Biotherapeutics' Times Interest Earned stood at $8.84 in 2022, then crashed by 32409.13% to -$2855.4 in 2023, then skyrocketed by 31.74% to -$1949.2 in 2024, then soared by 54.36% to -$889.62 in 2025, then surged by 47.47% to -$467.31 in 2026.
  • According to Business Quant data, Times Interest Earned over the past three periods came in at -$467.31, -$889.62, and -$1158.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.